Technologies

We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.

Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:

SITODIET is an innovative software that supports a translational approach to health’s state. It integrates various sources of physiological, behavioral, and psychological data to reduce the risks associated with the onset of lifestyle-related diseases (primary prevention), to support health professionals in early diagnosis (secondary prevention) or to manage the personalized therapy’s patient (tertiary prevention). SITODIETcollects data automatically, through actigraphy tools, as wristband or smartwatch, or manually

This form describes a programmable, autonomous and stand-alone imaging system for the acquisition and processing of images containing subjects whose size is larger than 1cm (e.g. gelatinous zooplankton, fishes, litter, manufacts), form the seafloor or along the water column, in shallow or deep waters. It is capable to recognize and classify the image content through pattern recognition algorithms that combine computer vision and artificial intelligence methodologies.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.